Covaxin phase 3 drug trial approved by SEC

The COVAXIN is an inactive vaccine that is developed by chemically treating the novel coronavirus samples to make it incapable of reproduction. That process leave the viral proteins intact, also including the spike protein of the coronavirus which it uses to enter the human cells.

The Bharat Biotech phase 3 trials effectiveness data has been approved by the Subject Expert Committee (SEC).

Covaxin had shown 77.8 per cent efficacy, according to the data submitted. As per the CNBC-TV18 reports, the phase 3 trials for the vaccine had been conducted over 25,800 subjects.

On June 21, Dr. VK Paul; member of the Centre’s topmost think tank NITI Aayog, said that the Hyderabad based vaccine maker had submitted it’s phase 3 trial efficacy data results of the COVAXIN vaccine to the Drug Controller General of India (DCGI) over the weekend. According to the results that had been published in the Lancet Infectious Disease Journal, it mentioned that the Phase 1 trials of the indigenously developed vaccine showed enhanced immune response without any serious side effects in the participants that had been enrolled for the phase 1 trials.

The Covaxin is an inactive vaccine that is developed by chemically treating the novel coronavirus samples to make it incapable of reproduction. That process leave the viral proteins intact, also including the spike protein of the coronavirus which it uses to enter the human cells.

On July 23, the Bharat Biotech has been expected to attend a pre-submission meeting with the World Health Organisation (WHO) for the emergency use listing of it’s COVID-19 vaccine candidate. The report also said that the approval from WHO would allow the vaccine maker to export its vaccines and facilitate an easier international travel of the Indian citizens who had been given the jab.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news delivered directly to your inbox.
You can unsubscribe at any time